Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…Abstract Number: 0021 • ACR Convergence 2020
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…Abstract Number: 0253 • ACR Convergence 2020
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…Abstract Number: 0270 • ACR Convergence 2020
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…Abstract Number: 0287 • ACR Convergence 2020
RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells
Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…Abstract Number: 0304 • ACR Convergence 2020
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…Abstract Number: 0788 • ACR Convergence 2020
Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery
Background/Purpose: The mucosal microbiome contributes to disease pathogenesis via local and systemic interaction with the host. The hallmark of this interaction in the physiological condition…Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…Abstract Number: 0887 • ACR Convergence 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…Abstract Number: 1143 • ACR Convergence 2020
The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus
Background/Purpose: A large global survey released by the World Lupus Federation showed that the awareness of SLE is low and many individuals have never heard…Abstract Number: 1270 • ACR Convergence 2020
Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years
Background/Purpose: Background: Few studies of systemic lupus erythematosus (SLE) have a follow-up duration long enough to evaluate the time trend of survival, particularly in Asian…Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…Abstract Number: 1302 • ACR Convergence 2020
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 150
- Next Page »